Considerable changes have occurred in the management of differentiated thyroid cancer
(DTC) during the past four decades, based on improved knowledge of the biology of DTC …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid
cancer (DTC) should be implemented in line with patients' risk stratification. Although …

Editor's note: SNMMI and the European Association of Nuclear Medicine periodically define
new standards/guidelines for nuclear medicine practice to help advance the science of …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the publication of the American Thyroid …

Background It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective
as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients with differentiated thyroid …

Background It is not clear whether the administration of radioiodine provides any benefit to
patients with low-risk thyroid cancer after a complete surgical resection. The administration …

Background Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Methods Six scientific Italian societies entitled to …

Differentiated thyroid cancer (DTC) is a rare malignant disease, although its incidence has
increased over the last few decades. It derives from follicular thyroid cells. Generally …